Early identification program for first-episode psychosis
Impact of an Early Identification Program for First-Episode Psychosis on the Duration of Untreated Psychosis. Multicenter, Randomized Stepped-wedge Study
This study tests a program that helps people with early signs of psychosis get the care they need faster to improve their chances of recovery.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 416 (estimated) |
| Ages | 15 Years to 35 Years |
| Sex | All |
| Sponsor | Centre Hospitalier Universitaire de Saint Etienne Academic / other |
| Locations | 6 sites (Bron and 5 other locations) |
| Trial ID | NCT05813457 on ClinicalTrials.gov |
What this trial studies
This study aims to evaluate the effectiveness of the PRESTO program, which facilitates early identification and access to specialized care for patients experiencing first-episode psychosis (FPE). By focusing on reducing the duration of untreated psychosis (DUP), the study seeks to improve the prognosis for individuals diagnosed with schizophrenia and related disorders. The intervention addresses barriers such as stigma and lack of awareness in the primary care network, which contribute to prolonged DUP. The study will also analyze factors influencing the implementation of this intervention for potential broader application.
Who should consider this trial
Good fit: Ideal candidates include individuals diagnosed with schizophrenia or related disorders who have not received prior neuroleptic treatment for more than six months.
Not a fit: Patients already receiving treatment for first-episode psychosis or those with brief psychotic states not requiring specific management may not benefit from this study.
Why it matters
Potential benefit: If successful, this program could significantly reduce the duration of untreated psychosis, leading to better long-term outcomes for patients.
How similar studies have performed: Other studies have shown that early intervention programs can effectively reduce the duration of untreated psychosis, suggesting a promising approach for this intervention.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients with a diagnosis of schizophrenia, schizoaffective disorder, schizophreniform disorder, or brief psychotic disorder established according to DMS 5 * Never having taken neuroleptic treatment for antipsychotic purposes, except for the current episode and for a duration of \< 6 month * Oral consent of the patient or, for minors, of his/her parents to participate in the study Exclusion Criteria: * Patients already treated and followed for FPE * Brief psychotic state not requiring specific management
Where this trial is running
Bron and 5 other locations
- Hospices Civils de Lyon — Bron, France (Recruiting)
- Chu Clermont-Ferrand — Clermont-Ferrand, France (Recruiting)
- Chu Grenoble — Grenoble, France (Recruiting)
- CHU de Montpellier — Montpellier, France (Recruiting)
- CHU de Nîmes — Nîmes, France (Recruiting)
- Chu Saint Etienne — Saint-Etienne, France (Recruiting)
Study contacts
- Principal investigator: Eric FAKRA, MD PhD — Centre Hospitalier Universitaire de Saint Etienne
- Study coordinator: Eric FAKRA, MD PhD
- Email: eric.fakra@chu-st-etienne.fr
- Phone: (0)477127885
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.